What do Wegovy results look like after a full year?

The decision most people are actually making at this point

If you are reading about one-year results, you are probably at one of two crossroads: you have been on Wegovy for several months and want to know what to expect next, or you are weighing up whether to start and trying to judge what a full year's commitment looks like. Both are reasonable questions, and they deserve honest answers rather than headline-grabbing averages.

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight plus at least one weight-related condition. Participants received 2.4mg semaglutide weekly alongside a reduced-calorie diet and increased activity. By week 68, the semaglutide group had lost an average of around 15% of body weight. The placebo group lost roughly 2.4%. That gap is substantial. But an average conceals a wide spread, some participants lost considerably more, others considerably less, and a meaningful minority did not reach 5% loss at all.

The NHS notes that if you have not lost at least 5% of your starting weight after six months at your maintenance dose, continuing treatment should be reviewed with your prescriber. That checkpoint matters when you are thinking about the one-year picture: the 12-month figure is, in part, the product of what happened in months one through six. If early progress was limited, a clinical conversation at six months is more useful than waiting for the annual review.

Why the rate of loss changes across the year

Weight loss with semaglutide follows a characteristic shape. If you are curious about what those first early changes actually feel like, our guide to what people typically notice in their first week on Wegovy sets out what is and is not realistic at that very early stage. As the body adapts and approaches a lower set point, the weekly losses become smaller. This is normal physiology, not treatment failure.

By months nine to twelve, many people on 2.4mg have reached something close to their nadir, the lowest weight the treatment is likely to produce at that dose. The NHS medicines information for semaglutide notes that Wegovy works alongside a reduced-calorie diet and increased physical activity; neither element is optional if you want the results the trial evidence describes. Patients in STEP 1 received structured lifestyle support throughout; people taking Wegovy privately without that support structure may see different results.

One honest thing worth saying: a lot of people reach the one-year mark feeling proud of their progress and quietly anxious about what happens next. That is an understandable place to be. The answer is usually a clinical conversation, not a guess. Our guide on how long Wegovy takes to work covers the earlier milestones in more detail for anyone mapping out the fuller timeline.

What happens when treatment continues, or stops

The STEP 4 withdrawal trial is the clearest evidence on this point. Participants who switched from semaglutide to placebo after 20 weeks regained around two-thirds of their lost weight within a further year. The implication is not subtle: the biology that drove the original weight gain does not disappear while someone is on treatment. Stopping the medicine tends to reverse a significant share of the loss.

This is why duration of treatment matters. NICE recommends semaglutide for a maximum of two years within specialist weight management services, a framing that acknowledges both the efficacy and the limits of a time-capped course. For people considering a longer-term private prescription, that is a conversation for a prescriber who knows the full clinical picture, not something to decide from a results page.

If you reach the one-year mark and feel your progress has stalled or reversed, it is worth reading about what to do when Wegovy stops working after a year before drawing conclusions. Dose, adherence, lifestyle factors and whether the 7.2mg option is clinically appropriate are all live questions.

Thinking about what Wegovy costs across a year of private treatment? Our cost context page for Wegovy in the UK sets out what transparent private pricing actually includes (consultation, prescription, delivery and aftercare) so you can compare like for like.

What the evidence means for your decision

A 15% average reduction is clinically meaningful. For someone starting at 100kg, that is 15kg, enough to reduce blood pressure, improve cholesterol and ease joint load in most people. But it is an average from a controlled trial with structured lifestyle support. Real-world results cluster around that figure, with some people doing better and others doing less well.

The factors that most reliably predict a stronger outcome are: reaching and tolerating the 2.4mg maintenance dose, sustained changes to diet quality (protein, fibre, calorie awareness), and some form of regular physical activity. None of these are surprising. What the medicine adds is a meaningful reduction in appetite and food noise that makes those changes easier to sustain. For a closer look at how progress builds through the earlier part of treatment, our page on what results typically look like after one month on Wegovy gives useful context on what to expect before the one-year picture comes into view.

Semaglutide is a prescription-only medicine, and whether it is appropriate for you (including which dose and for how long) is a clinical judgement. You can explore the broader picture on our Wegovy results overview, or if you are ready to talk to a prescriber, check your eligibility with our clinical team.